Filtered By:
Condition: Cholesterol
Drug: Vytorin
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Conclusion: The price of alirocumab would have to be reduced considerably to be cost-effective. Because substantial reductions already have occurred, we believe that timely, independent cost-effectiveness analyses can inform clinical and policy discussions of new drugs as they enter the market. Primary Funding Source: University of California, San Francisco, and Institute for Clinical and Economic Review. PMID: 30597485 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 1, 2019 Category: Internal Medicine Authors: Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K Tags: Ann Intern Med Source Type: research